Morepen Labs Jumps 12% on Launch of ‘Empamore’ – Details Inside

Current share price of Morepen Laboratories(Morepen Labs): %{share_amount} On & March 31, 2025, Morepen Labs share price was trading actively since the stock increased by 11.63 percent reaching the intraday peak of 47.78 Rs per share. The increase in the price of Morepen Lab shares came after the firm stated that it has launched ‘Empamore’ treatment which uses Empamore for therapeutical care of Type 2 Diabetes Mellitus (T2DM), heart failure along with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD).

“The company claimed it has European DMF already, and Empagliflozin manufacturing (API) is done in their facilities which are approved by USFDA.”  

In addition to the previously mentioned products, Empagliflozin is also offered in 10mg and 25mg strengths, plus Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg). Empagliflozin is also known as a SGLT2 inhibitor diabetes is unimaginably commom in India. Morepen Labs launching Empamore comes at a time where almost 136 million people are considered pre-diabetic and the current diabetes market is estimated to increase at a rate of 10.9% annually. This puts the company in a position where they need to provide a sustainable answer to the ever-increasing diabetes problem in India. Ashutosh Sharma, Vice President of Sales and Marketing at Morepen Laboratories commented, “Morepen puts every effort in changing the assumption that only premium healthcare is available by providing high value solutions at the price of lower value products. The launch of Empamore brings a change to the lives of millions of people, as with it, one can manage diabetes with high efficiency but low strain on finances, we help people assume full control to their health as we aim to support their chronic conditions at minimal expense.”  

Currently, Morepen Labs has revealed that a lot of patients do not have access to Empagliflozin tablets due to the high prices.

By offering Empamore at a much reduced price, Morepen Labs intends to capture a sizable portion of the diabetes market share in India which is expanding at a rapid pace and at the same time make sure that quality treatment is accessible to all patients rather than a privilege. 

About Morepen Labs 

Morepen Laboratories is among the top pharmaceutical companies in India that focus on the manufacturing, development, and marketing of active pharmaceutical ingredients, branded and generic formulations, and home health care products. 

Incorporated in 1984, the company has received significant international recognition due to its exports to more than 80 nations. Morepen’s commitment to quality and ethical sourcing enables the brand to deliver healthcare provisions across many therapeutic areas including multispecialty, cardiac, and diabetes healthcare. 

The company is engaged in key areas like providing APIs where it is a leader in exports for products like Loratadine, Montelukast, and Atorvastatin. 

Morepen also manufactures a number of finished formulations which include prescription drugs as well as OTC medicines. 

The company provides home health products, such as diagnostic and glucometer devices. 

As per the BSE, the market capitalistaion of Morepen Labs is Rs 2,583.05 crore.

Shares of Morepen Labs are up 10.14 per cent at Rs 47.14 per share at 11:00 AM. Moreover, BSE Sensex is up 1.15 per cent as well, sitting at 75,020.16.